PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q88025

Julia CIANCI, et al.

Appln. No.: 10/536,504

Group Art Unit: 1623

Confirmation No.: 6545

Examiner: Elli PESELEV

Filed: December 19, 2005

For:

NOVEL CHEMICAL COMPOUNDS AND THEIR USE

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

December 9, 2008:

Sir:

Please review and enter the following remarks summarizing the interview conducted on

REMARKS

An Examiner's Interview Summary Record (PTO-413) was mailed December 15, 2008.

During the interview, the following was discussed:

- 1. Brief description of exhibits or demonstration: None.
- 2. Identification of claims discussed: All.
- 3. Identification of art discussed: None.
- 4. Identification of principal proposed amendments: Applicants proposed amending claim 1 to further define linker (L) and the pharmacokinetic regulator (Y).
 - 5. Brief Identification of principal arguments: None.
 - 6. Indication of other pertinent matters discussed: None.

Attorney Docket No. Q88025

Statement of Substance of Interview Application No. 10/536,504

7. Results of Interview: Agreement was not reached.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,

Registration No. 40,641

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373
CUSTOMER NUMBER

Date: March 24, 2009